About Cabazitaxel
            
            Class: | Antineoplastic agent, Taxane derivative  
Use: | Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with a docetaxel-containing treatment regimen  
Adult dose: | 25 mg/m² administered intravenously every 3 weeks, in combination with prednisone  
Pediatric dose: | Safety and efficacy in pediatric patients have not been established; not recommended for use in children  
Side effects: | Neutropenia, anemia, fatigue, diarrhea, nausea, vomitin
         
        
            
                
                
                    
                        Drug Class
                    
                    Antineoplastic agent, Taxane derivative
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with a docetaxel-containing treatment regimen
                 
                
                
                    
                        Storage Requirements
                    
                    Store at 20°C to 25°C (68°F to 77°F); protect from light; do not freeze
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Sanofi Aventis LLC, U.S.A
                    
                    
                    Package Size
                    1.5ml Vial + 5.7ml Diluent
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 26311.60
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        25 mg/m² administered intravenously every 3 weeks, in combination with prednisone
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy in pediatric patients have not been established; not recommended for use in children
                    
                 
                
                
                    
                        Side Effects
                    
                    Neutropenia, anemia, fatigue, diarrhea, nausea, vomiting, peripheral neuropathy, and hypersensitivity reactions
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to cabazitaxel or any component of the formulation; severe bone marrow suppression; pregnancy and breastfeeding
         
        
        
            
                Important Warnings
            
            Risk of severe neutropenia and associated infections; monitor blood counts; may cause hypersensitivity reactions; use caution in patients with hepatic impairment; potential for fetal harm if administered during pregnancy
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.